Advertisement
Advertisement
NBIX
Neurocrine Biosciences Inc
130.53
USDSponsored
+0.75
+0.58%
Mar 16, 12:26 UTC -4
Open
NBIX Earnings Reports
Positive Surprise Ratio
NBIX beat 16 of 40 last estimates.
40%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$790.45M
/$1.22
Implied change from Q4 25 (Revenue/ EPS)
-1.87%
/-17.57%
Implied change from Q1 25 (Revenue/ EPS)
+38.05%
/+1425.00%
Neurocrine Biosciences Inc earnings per share and revenue
On Feb 11, 2026, NBIX reported earnings of 1.48 USD per share (EPS) for Q4 25, missing the estimate of 1.91 USD, resulting in a -22.89% surprise. Revenue reached 805.50 million, compared to an expected 807.79 million, with a -0.28% difference. The market reacted with a -10.43% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 19 analysts forecast an EPS of 1.22 USD, with revenue projected to reach 790.45 million USD, implying an decrease of -17.57% EPS, and decrease of -1.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Guardian Pharmacy Services, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.25
Actual
$0.37
Surprise
+45.10%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.45
Actual
-$0.42
Surprise
+6.77%
Esperion Therapeutics, Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.24
Actual
$0.22
Surprise
-10.46%
Nektar Therapeutics
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.52
Actual
-$1.78
Surprise
+29.47%
Zevra Therapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
$0.05
Actual
$0.21
Surprise
+311.76%
SIGA Technologies Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
-Actual
-$0.08
Surprise
-
Nature's Sunshine Products Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.19
Actual
$0.30
Surprise
+54.80%
Century Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.25
Surprise
+13.49%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.51
Surprise
+37.05%
FAQ
What were Neurocrine Biosciences Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Neurocrine Biosciences Inc reported EPS of $1.48, missing estimates by -22.89%, and revenue of $805.50M, -0.28% below expectations.
How did the market react to Neurocrine Biosciences Inc's Q4 2025 earnings?
The stock price moved down -10.43%, changed from $137.44 before the earnings release to $123.10 the day after.
When is Neurocrine Biosciences Inc expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Neurocrine Biosciences Inc's next earnings report?
Based on 19
analysts, Neurocrine Biosciences Inc is expected to report EPS of $1.22 and revenue of $790.45M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement